Projected worldwide disease burden from giant cell arteritis by 2050

Journal of Rheumatology

Volumn 42, Issue 1, 2015, Pages 119-125

  De Smit, Elisabeth ^a,b   Palmer, Andrew J ^c   Hewitt, Alex W ^a,c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Ear Hospital   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Blindness; Costs; Disease burden; Giant cell arteritis; Incidence; Prevalence

Indexed keywords

CORTICOSTEROID;

AGING; ARTICLE; BLINDNESS; ETHNICITY; FRACTURE; GENDER; GIANT CELL ARTERITIS; HEALTH CARE COST; HUMAN; INCIDENCE; MORBIDITY; PREVALENCE; RISK REDUCTION; SOCIAL SUPPORT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL IMPAIRMENT; COST OF ILLNESS; ECONOMICS; FORECASTING; HEALTH; STATISTICS AND NUMERICAL DATA;

COST OF ILLNESS; FORECASTING; GIANT CELL ARTERITIS; GLOBAL HEALTH; HEALTH CARE COSTS; HUMANS; INCIDENCE; PREVALENCE;

EID: 84920456915     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140318     Document Type: Article

References (50)

1. Borchers AT, Gershwin ME. Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 2012;11:A544-54.
2. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol 2008;35:88-95.
3. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
4. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8.
5. United Nations. Population ageing and development 2012. [Internet. Accessed September 25, 2014.] Available from: www.un.org/en/development/desa/population/publications/pdf/ageing/2012PopAgeingandDev-WallChart.pdf.
6. PRISMA. The PRISMA statement. [Internet. Accessed September 25, 2014.] Available from: www.prisma-statement.org.
7. United Nations, Department of Economic and Social Affairs. World population prospects: The 2012 revision. [Internet. Accessed September 25, 2014.] Available from: esa.un.org/wpp/Excel-Data/Interpolated.htm.
8. Roberts CB, Hiratsuka Y, Yamada M, Pezzullo ML, Yates K, Takano S, et al. Economic cost of visual impairment in Japan. Arch Ophthalmol 2010;128:766-71.
9. Kermani TA, Schäfer VS, Crowson CS, Hunder GG, Gabriel SE, Matteson EL, et al. Increase in age at onset of giant cell arteritis: A population-based study. Ann Rheum Dis 2010;69:780-1.
10. Crow RW, Katz BJ, Warner JE, Alder SC, Zhang K, Schulman S, et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci 2009;64:365-9.
11. Cotch MF. The socioeconomic impact of vasculitis. Curr Opin Rheumatol 2000;12:20-3.
12. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: A systematic literature review. Clin Ther 2011;33:1413-32.
13. Robinson R. Costs and cost-minimisation analysis. BMJ 1993;307:726-8.
14. Simoens S. Health economic assessment: A methodological primer. Int J Environ Res Public Health 2009;6:2950-66.
15. Haugeberg G, Irgens KA, Thomsen RS. No major differences in incidence of temporal arteritis in northern and western Norway compared with reports from southern Norway. Scand J Rheumatol 2003;32:318-9.
16. Baldursson O, Steinsson K, Björnsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum 1994;37:1007-12.
17. Nordborg C, Johansson H, Petursdottir V, Nordborg E. The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population. Rheumatology 2003;42:549-52.
18. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006;65:1093-8.
19. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996;23:112-9.
20. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, Perez-Alvarez R, Gonzalez-Juanatey C, Sanchez-Andrade A, et al. Giant cell arteritis in northwestern Spain: A 25-year epidemiologic study. Medicine 2007;86:61-8.
21. Abdul-Rahman AM, Molteno AC, Bevin TH. The epidemiology of giant cell arteritis in Otago, New Zealand: A 9-year analysis. N Z Med J 2011;124:44-52.
22. Bas-Lando M, Breuer GS, Berkun Y, Mates M, Sonnenblick M, Nesher G. The incidence of giant cell arteritis in Jerusalem over a 25-year period: Annual and seasonal fluctuations. Clin Exp Rheumatol 2007;25:S15-7.
23. Ramstead CL, Patel AD. Giant cell arteritis in a neuro-ophthalmology clinic in Saskatoon, 1998-2003. Can J Ophthalmol 2007;42:295-8.
24. Barrier J, Pion P, Massari R, Peltier P, Rojouan J, Grolleau JY. [Epidemiologic approach to Horton's disease in the department of Loire-Atlantique. 110 cases in 10 years (1970-1979)]. [Article in French] Rev Med Interne 1982;3:13-20.
25. Salvarani C, Macchioni P, Zizzi F, Mantovani W, Rossi F, Castri C, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991;34:351-6.
26. Dunstan E, Lester SL, Rischmueller M, Dodd T, Black R, Ahern M, et al. Epidemiology of biopsy-proven giant cell arteritis in South Australia. Intern Med J 2014;44:32-9.
27. Pamuk ON, Dönmez S, Karahan B, Pamuk GE, Cakir N. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data. Clin Exp Rheumatol 2009;27:830-3.
28. Waern M, Rubenowitz E, Runeson B, Skoog I, Wilhelmson K, Allebeck P. Burden of illness and suicide in elderly people: case-control study. BMJ 2002;324:1355.
29. Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, et al. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics 2006;24:193-205.
30. Öberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: A systematic review. BMJ Open 2013;3:e003471.
31. Souza AW, Okamoto KY, Abrantes F, Schau B, Bacchiega AB, Shinjo SK. Giant cell arteritis: A multicenter observational study in Brazil. Clinics 2013;68:317-22.
32. Gilbert JL, Coe MD, Nam MH, Kolsky MP, Barth WF. Giant cell arteritis in AJ Americans. J Clin Rheumatol 1999;5:116-20.
33. Wang X, Hu Z, Lu W, Tang X, Zeng L, Zhang J, et al. Giant cell arteritis: A rare disease in Asians. J Clin Rheumatol 2009;15:48.
34. Cullen JF, Chan CM, Chuah KL. Giant cell arteritis (temporal arteritis, cranial arteritis) and a case from Singapore. Singapore Med J 2003;44:306-8.
35. Lie JT. Giant cell temporal arteritis in a Laotian Chinese. J Rheumatol 1992;19:1651-2.
36. Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: The first government-supported nationwide survey. Arthritis Rheum 2003;49:594-8.
37. Imai N, Kuroda R, Konishi T, Serizawa M, Kobari M. Giant cell arteritis: clinical features of patients visiting a headache clinic in Japan. Intern Med 2011;50:1679-82.
38. Pereira LS, Yoon MK, Hwang TN, Hong JE, Ray K, Porco T, et al. Giant cell arteritis in Asians: A comparative study. Br J Ophthalmol 2011;95:214-6.
39. Shah A, Jain S. Epidemiology of giant cell arteritis in an Arab population: A 22-year study. Ethnic variation in incidence of giant cell arteritis. Br J Ophthalmol 2008;92:724-5.
40. Singh S, Balakrishnan C, Mangat G, Samant R, Bambani M, Kalke S, et al. Giant cell arteritis in Mumbai. J Assoc Physicians India 2010;58:372-4.
41. Laldinpuii J, Sanchetee P, Borah AL, Ghose M, Borah NC. Giant cell arteritis (temporal arteritis): A report of four cases from north east India. Ann Indian Acad Neurol 2008;11:185-9.
42. Guerra A, Magraner M, Serrano L, Bredy R. Temporal arteritis in Puerto Rico Hispanics. Bol Asoc Med P R 2006;98:304-11.
43. Alba MA, Mena-Madrazo JA, Reyes E, Flores-Suárez LF. Giant cell arteritis in Mexican patients. J Clin Rheumatol 2012;18:1-7.
44. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994;14:38-44.
45. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998;125:509-20.
46. Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, et al. Risk factors for visual loss in giant cell (temporal) arteritis: A prospective study of 174 patients. Am J Med 2001;111:211-7.
47. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550-5.
48. Foroozan R, Deramo VA, Buono LM, Jayamanne DG, Sergott RC, Danesh-Meyer H, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003;110:539-42.
49. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007;125:544-50.
50. Yang YH, Morand E, Leech M. Annexin A1: potential for glucocorticoid sparing in RA. Nat Rev Rheumatol 2013;9:595-603.